搜尋結果
Up 165% This Year, Will Dyne Therapeutics Continue Its Stellar Run?
Forbes· 2 日前: DYN), a biotechnology company focused on advancing genetically driven muscle diseases ... ...
$20M Fund For Connecting Early-Stage Israeli Startups To New York City
Forbes· 2 日前As the name implies, the $20 million fund is focused on pre-seed ...
Forbes Daily: AI Darling Nvidia Faces Sky-High Earnings Expectations
Forbes· 2 日前Consumer spending powers the U.S. economy, but there are signs consumers could be growing ...
Australia to ban knock-offs of popular weight-loss drugs Ozempic, Mounjaro
Reuters· 2 日前Australia said on Wednesday it will ban copies of drugs used for weight loss such as Ozempic and Mounjaro ...
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
CNBC· 2 日前A patient injects herself with an insulin pen. The rivalry between Eli Lilly and Novo ... ...
Eli Lilly stock hits new highs after a regulatory win in China. This is a big deal
CNBC· 2 日前Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" ...
JPMorgan says there's a new GLP-1 drug player and its shares can rally 80%
CNBC· 2 日前Structure Therapeutics is an overlooked player in the GLP-1 market, and could one ...
US FDA staff says Guardant's test may fail to detect some pre-cancerous tumors
Reuters· 3 日前, opens new tab experimental blood test for a cancer of colon or rectum may fail to detect some ...
Nestle set to sell $5 pizza, sandwiches for Wegovy, Ozempic users
Reuters· 3 日前, opens new tab will market a new, $5 line of frozen pizzas and protein-enriched pastas ... ...
Nestle to launch Vital Pursuit frozen-food brand targeting GLP-1 users
CNBC· 3 日前Nestle is launching a new frozen-food brand, Vital Pursuit, aimed at the growing & ...